University Of Zürich

Biogen International Neuroscience Gmbh

Neurimmune Holding Ag

New York University

Delenex Therapeutics Ag

Biogen Idec International Neuroscience Gmbh

Unversität Zürich

Boehringer Ingelheim Pharma Kg

Nsc Therapeutics Gmbh

University of Zurich Prorektorat Forschung

Roger Nitsch

Jan Grimm

Christoph Hock

Paul H Weinreb

Fabio Montrasio

Christoph Esslinger

Andreas Weihofen

Maria Grazia Barenco Montrasio

Marlen Knobloch

Kathrin Tissot

Marcel Maier

Jean-Luc Baeriswyl

Lihe Su

Feng Chen

Omar Quintero-Monzon

Janaky Coomaraswamy

Karsten Henco

Adrian Auf Der Maur

Stefan Ewert

Tobias Welt

Susann Cattepoel

Anja Zeller

Jordan Mcafoose

Abraham Fisher

Marion Wienrich

Alfred Zippelius

Dirk Jäger

Klaus Mendla

Andreas Raschig

Markus Rudin

Stefan Grathwohl

Dieter Horst Meier

Cornelia Dorner-Ciossek

Klaus Bornemann

Alexander Knuth

Felicitas Kranz

Thomas Müggler

Uwe Konietzko

Norbert Göbels

Holger Moch

Irene Abela

Jürgen Götz

Sandra Künzle

Antonella Santuccione Chadha

Christoph Prof Hock

Mario Merlini

Jordan McAfoose

Provided are M1 muscarinic acetylcholine receptor (mAChR) agonists, for use in the treatment of a neurological or neurodegenerative disease by promoting microglia and/or macrophage viability and/or activation. Microglia and macrophage survival and activation are thereby achieved by increasing levels of sTREM2 released by microglia cells. In addition, pharmaceutical compositions and methods of preparing the same are described, which are suitable for the treatment or prevention of conditions or diseases that require microglia and/or macrophage modulation, as well as methods for monitoring treatments and enhancing microglia and/or macrophage survival and/or activation.

Compounds and methods for use in the treatment of microglia-mediated disorders

Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.

Human anti-SOD1 antibodies

Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

TDP-43 specific binding molecules

A treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.

Method of providing patient specific immune response in amyloidoses and protein aggregation disorders

Provided are novel human &#x3b1;-synuclein-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for &#x3b1;-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Human anti-alpha-synuclein antibodies

Provided are anti-human &#x3b1;-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human &#x3b1;-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human &#x3b1;-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Anti-alpha synuclein binding molecules

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Method of providing disease-specific binding molecules and targets

Methods of treating Alzheimer's disease

Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for &#x3b1;-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

Human anti-tau antibodies

Growing community of inventors

Zumikon, Switzerland

Roger Nitsch